Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next
New York, February 8, 2026, 08:54 EST — Market closed Roivant Sciences Ltd (ROIV.O) shares will be back on watchlists when U.S. trading resumes on Monday after a sharp Friday rally pushed the stock to $25.82 at the close, up 22.14% on the day. Volume topped 24 million shares, far above Roivant’s recent run rate. (Twelve Data) The move followed Roivant’s release of positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, a hard-to-treat inflammatory skin disease, and the company’s statement that it submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration for brepocitinib in